<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913104</url>
  </required_header>
  <id_info>
    <org_study_id>18-26819</org_study_id>
    <nct_id>NCT03913104</nct_id>
  </id_info>
  <brief_title>Mail Order Mifepristone Study</brief_title>
  <official_title>Feasibility and Acceptability of Dispensing Mifepristone Via Mail Order Pharmacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the feasibility, acceptability, and effectiveness of dispensing&#xD;
      mifepristone via a mail-order pharmacy. The investigators will recruit patients at up to 10&#xD;
      primary care and internal medicines sites not currently providing abortion services around&#xD;
      the country, as well as abortion clinic sites. Patients will go through routine in clinic&#xD;
      visits to determine eligibility and then will receive the medications in the mail at their&#xD;
      preferred address. The investigators will survey patients 3 and 14 days after the initial&#xD;
      clinic visit and interview providers at the end of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective cohort study of patients obtaining medication abortion via mifepristone&#xD;
      dispensed from an online mail order pharmacy. After an initial pilot test with 25 patients,&#xD;
      the investigators will identify 10 clinics to participate in the study. The study team will&#xD;
      train primary care providers not currently providing abortion to provide medication abortion&#xD;
      with the medications dispensed via mail order pharmacy. The investigators aim to recruit up&#xD;
      to 650 patients for this study across all the sites. Patients will come in for an initial&#xD;
      consult visit at the study site and then receive their medications at a preferred address&#xD;
      within 3 days of the initial visit. Study participants will fill out surveys about their&#xD;
      experience and feedback about the acceptability of the process; this will occur at 3 and 14&#xD;
      days after the initial recruitment visit. The investigators will also collect clinic data&#xD;
      from patients and clinic sites to track clinical outcomes. And the investigators will&#xD;
      interview providers at the end of the study to better understand their experiences&#xD;
      prescribing mifepristone via mail-order.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective Cohort</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who report positive experience.</measure>
    <time_frame>Day 14 following initial medication abortion visit</time_frame>
    <description>Proportion of patients reporting whether they would use the mail order service again if they needed another abortion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who report timely delivery of medication.</measure>
    <time_frame>Day 3 following initial medication abortion visit</time_frame>
    <description>Proportion of patients who receive medications by Day 2 and Day 3 and proportion of patients who indicate their confidentiality was maintained when receiving medications by mail. The investigators will also estimate the proportion of patients who report that medications were lost, stolen or damaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have a complete abortion</measure>
    <time_frame>Up to 6 weeks after initial medication abortion visit.</time_frame>
    <description>Using electronic health record data related to abortion, the investigators will estimate the proportion of patients who experience a complete abortion and the proportion of patients who experience complications, including adverse or severe adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">425</enrollment>
  <condition>Abortion Early</condition>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Medication Abortion Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.</description>
    <arm_group_label>Medication Abortion Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women seeking medication abortion through 63 days gestation&#xD;
&#xD;
          -  Eligible for MifeprexⓇ at a study site&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Willing and able to participate in the study, including willing and able to receive&#xD;
             medications at home or other preferred address within 3 days of initial medication&#xD;
             abortion visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Not seeking medication abortion&#xD;
&#xD;
          -  under the age of 15&#xD;
&#xD;
          -  Over 63 days gestation&#xD;
&#xD;
          -  Contraindicated for medication abortion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Grossman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Raifman, MSc</last_name>
    <phone>510-986-8970</phone>
    <email>sarah.raifman@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Highland Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Ho, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephanie Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lela Bachrach, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lela Bachrach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Rocky Mountains</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Firstenberg</last_name>
    </contact>
    <investigator>
      <last_name>Kristina Tocce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Wohler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diana Wohler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Comprehensive Wellness Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamer Middleton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Tier Women's Health Services</name>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <zip>13850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Seibold-Simpson, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Susan Seibold-Simpson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Cousins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware County Women's Center</name>
      <address>
        <city>Chester</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtiss Hannum, NP</last_name>
    </contact>
    <investigator>
      <last_name>Curtiss Hannum, NP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Reproductive Health Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grace Ferguson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brown Family Medicine</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Arena, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Arena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifespan</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Sobota, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mindy Sobota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Daniel Grossman</investigator_full_name>
    <investigator_title>Professor and Director of ANSIRH</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

